Find a Viewpoint

Antimicrobial Viewpoints are articles in which experts in different areas of antimicrobial resistance share their knowledge and opinions about the current status and the future challenges of this field. You can read our editorial and ethics policies for these articles here

<br>The antibiotic R&D landscape in Japan</br><em> – by Norio Ohmagari</em>
25 November 2020

The antibiotic R&D landscape in Japan – by Norio Ohmagari

more
<br>Tackling the drug-resistance pandemic – 2020 and beyond</br><em> – by Laura J.V. Piddock</em>
23 November 2020

Tackling the drug-resistance pandemic – 2020 and beyond – by Laura J.V. Piddock

more
<br>Why are new antibacterials failing as commercial products?</br><em> – by Patricia A. Bradford</em>
19 November 2020

Why are new antibacterials failing as commercial products? – by Patricia A. Bradford

more
<br>COVID-19: Coinfection, secondary bacterial infections and AMR in India</br><em> – by Venkatasubramanian Ramasubramanian</em>
12 November 2020

COVID-19: Coinfection, secondary bacterial infections and AMR in India – by Venkatasubramanian Ramasubramanian

more
<br>Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic</br><em> – by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone </em>
15 October 2020

Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom ...

more
<br>A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need</br><em> – by John Rex</em>
6 October 2020

A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need ...

more

Share

FacebookTwitterRedditLinkedInEmail
✕

Newsletter

Subscribe to our newsletter to stay up-to-date about our webinars, conferences and other activities.



View previous newsletter

Go to Top